Different efficacies of neutralizing antibodies and antiviral drugs on SARS-CoV-2 Omicron subvariants, BA.1 and BA.2
Hirofumi Ohashi(Aichi Medical University), Koichi Watashi(Tokyo University of Science), Shuetsu Fukushi(National Institute of Infectious Diseases), Tadaki Suzuki(National Institute of Infectious Diseases), Takayuki Hishiki(National Institute of Infectious Diseases), Hideki Ebihara(National Institute of Infectious Diseases), Shingo Iwami(Kyushu University), Kwang Su Kim(Nagoya University), Kana Tsuchimoto(National Institute of Infectious Diseases), Kaho Shionoya(Tokyo University of Science), Saya Moriyama(Cornell University), Shoya Iwanami(Nagoya University), Ken Maeda(Yamaguchi University), Hideki Hasegawa(University of California, Los Angeles), Yudai Kuroda(Yamaguchi University), Hitomi Kinoshita(National Institute of Infectious Diseases), Souichi Yamada(National Institutes of Health), Joohyeon Woo(Nagoya University), Shinji Watanabe(University of Miyazaki), Noriko Kishida(National Institute of Infectious Diseases), Daisuke Akazawa(National Institute of Infectious Diseases), Tsukasa Yamamoto(National Institute of Infectious Diseases), Yoshimasa Takahashi(Hokkaido Pharmaceutical University)
Cited by 33
Related Papers
The lipid droplet is an important organelle for hepatitis C virus production
|Nature Cell Biology|2007|1.2k
Taxonomy of the order Mononegavirales: update 2016
|Archives of Virology|2016|506
Negative regulation of the RIG-I signaling by the ubiquitin ligase RNF125
|Proceedings of the National Academy of Sciences|2007|474